Sorbent Therapeutics Secures $21,800,000 Series B Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=2c8bb69b-2b90-4352-8095-96a52399a5ee&Preview=1 -
Date
9/13/2010 -
Company Name
Sorbent Therapeutics -
Mailing Address
750 East Bunker Court Vernon Hills, IL 60061 -
Company Description
Sorbent Therapeutics is a biopharmaceutical company focused on the development of adaptable non-absorbed polymeric drugs to satisfy unmet clinical needs in large markets such as End Stage Renal Disease (ESRD), Congestive Heart Failure (CHF), Chronic Kidney Disease (CKD), and Hypertension. -
Website
http://www.sorbentrx.com -
Transaction Type
Venture Equity -
Transaction Amount
$21,800,000 -
Transaction Round
Series B -
Proceeds Purposes
Sorbent will use the capital to advance the clinical development of its lead drug candidate CLP-1001 for patients with sodium and fluid overload or risk for hyperkalemia in renal and cardiovascular diseases, such as End Stage Renal Disease and Congestive Heart Failure. -
M&A Terms
-
Venture Investor
AgeChem Venture Fund -
Venture Investor
CMEA Ventures -
Venture Investor
Sofinnova Ventures -
Venture Investor
Dow Venture Capital -
Venture Investor
ARCH Venture Partners
